Also the EAU guidelines state that PSAV and PSADT have limited use in the diagnosis of prostate cancer due to BPH, variations in interval between PSA measurements, and acceleration/deceleration of PSAV and PSADT over time [64]. Here, KLK3 is linked to benign prostatic hyperplasia.